The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

Mohab Alexander, James R Brasic

Research output: Contribution to journalArticle

Abstract

FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

Original languageEnglish (US)
Pages (from-to)566-567
Number of pages2
JournalClinical Nuclear Medicine
Volume31
Issue number9
DOIs
StatePublished - Sep 2006

Fingerprint

Esophageal Neoplasms
Positron-Emission Tomography
Neoplasm Metastasis
Glucose
Carcinoma
Bone and Bones
Anorexia
Deglutition Disorders
Fatigue
Weight Loss
Neoplasms
Therapeutics
Physicians

Keywords

  • Carcinoma
  • Dysphagia
  • Esophagus
  • Malignancy
  • Metastases
  • Radiation therapy

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET). / Alexander, Mohab; Brasic, James R.

In: Clinical Nuclear Medicine, Vol. 31, No. 9, 09.2006, p. 566-567.

Research output: Contribution to journalArticle

@article{d3102eabab0641389b7f803930f19fde,
title = "The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)",
abstract = "FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.",
keywords = "Carcinoma, Dysphagia, Esophagus, Malignancy, Metastases, Radiation therapy",
author = "Mohab Alexander and Brasic, {James R}",
year = "2006",
month = "9",
doi = "10.1097/01.rlu.0000233350.01580.c2",
language = "English (US)",
volume = "31",
pages = "566--567",
journal = "Clinical Nuclear Medicine",
issn = "0363-9762",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - The diagnosis of esophageal cancer by 2-deoxy-2-F-18 fluoro-D-glucose positron emission tomography (F-18 FDG PET)

AU - Alexander, Mohab

AU - Brasic, James R

PY - 2006/9

Y1 - 2006/9

N2 - FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

AB - FDG PET plays an essential role in the diagnosis and treatment of patients with esophageal carcinoma. A 67-year-old man, who presented with dysphagia, fatigue, weakness, anorexia, anergia, and weight loss, underwent Tc-99m bone scan, CT, and FDG PET imaging. The bone scan and CT were consistent with a malignancy. Whole-body FDG PET demonstrated multiple metastases in various locations and helped the treating physicians to institute appropriate therapy. The identification of metastases by FDG PET is a critical component of the initial evaluation of a patient with esophageal carcinoma for the diagnosis and treatment of the primary malignancy and metastases.

KW - Carcinoma

KW - Dysphagia

KW - Esophagus

KW - Malignancy

KW - Metastases

KW - Radiation therapy

UR - http://www.scopus.com/inward/record.url?scp=33747618246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747618246&partnerID=8YFLogxK

U2 - 10.1097/01.rlu.0000233350.01580.c2

DO - 10.1097/01.rlu.0000233350.01580.c2

M3 - Article

C2 - 16921288

AN - SCOPUS:33747618246

VL - 31

SP - 566

EP - 567

JO - Clinical Nuclear Medicine

JF - Clinical Nuclear Medicine

SN - 0363-9762

IS - 9

ER -